» Articles » PMID: 35462992

Strengths, Weaknesses, Opportunities and Threats (SWOT) Analysis of the Implementation of Public Health Policies on HTLV-1 in Brazil

Overview
Specialty General Medicine
Date 2022 Apr 25
PMID 35462992
Authors
Affiliations
Soon will be listed here.
Abstract

Human T lymphotropic virus 1 (HTLV-1) is a public health issue for most countries and imposes important consequences on patients' health and socioeconomic status. Brazil is one of the global leaders of the public health response to these viruses. The country has challenges to overcome to implement meaningful policies aiming to eliminate HTLV-1/2. An analysis of strengths, weaknesses, opportunities, and threats (SWOT) for the implementation of public health policies on HTLV-1/2 was performed. The strengths identified were the Brazilian Unified Health System (SUS); Brazilian expertise in public health programs successfully implemented; currently available policies targeting HTLV; and strong collaboration with researchers and patient's representative. Lack of awareness about HTLV, insufficient epidemiological data, lack of reference centers for patient care, insufficient availability of confirmatory tests, lack of universal antenatal screening, and absence of cost-effectiveness studies were identified as weaknesses. Some interesting opportunities included the increased interest from international organizations on HTLV, possibility of integrating HTLV into other programs, external funding for research, available online platforms, opportunity to acquire data from HTLV-1/2 surveillance to gather epidemiological information, and HTLV policies that were implemented independently by states and municipalities. In addition to the COVID-19 pandemic, existing demands from different diseases, the country's demography and its marked sociocultural diversity and the volatility of the technical team working with HTLV-1/2 at the Brazilian Ministry of Health are threats to the implementation of public policies on HTLV-1/2. This SWOT analysis will facilitate strategic planning to allow continuous progress of the Brazilian response to HTLV-1/2 infection.

Citing Articles

Brazil takes a leap towards the elimination of HTLV-1 vertical transmission.

Rosadas C, Barreira D, Gaspar P, Aragon M, Oliveira A, Assone T Lancet Reg Health Am. 2024; 39:100888.

PMID: 39381433 PMC: 11460242. DOI: 10.1016/j.lana.2024.100888.


Perspectives on the COVID-19 Vaccination Rollout in 17 Countries: Reflexive Thematic and Frequency Analysis Based on the Strengths, Weaknesses, Opportunities, and Threats (SWOT) Framework.

Kopilas V, Nasadiuk K, Martinelli L, Lhotska L, Todorovic Z, Vidmar M JMIR Hum Factors. 2024; 11:e44258.

PMID: 38373020 PMC: 10896317. DOI: 10.2196/44258.


HTLV infection and cessation of breastfeeding: context and challenges in implementing universal prevention policies in Brazil.

Rosadas C, Miranda A Epidemiol Serv Saude. 2023; 32(2):e2023565.

PMID: 37729266 PMC: 10510609. DOI: 10.1590/S2237-96222023000200025.


Evaluation of massive education in prison health: a perspective of health care for the person deprived of freedom in Brazil.

Valentim J, Dias-Trindade S, Oliveira E, Romao M, Fernandes F, Caitano A Front Public Health. 2023; 11:1239769.

PMID: 37680276 PMC: 10480506. DOI: 10.3389/fpubh.2023.1239769.


HTLV-1 and HTLV-2 infections in patients with endemic mycoses in São Paulo, Brazil: A cross-sectional, observational study.

Caterino-de-Araujo A, Campos K, Alves I, Vicentini A Lancet Reg Health Am. 2023; 15:100339.

PMID: 36778068 PMC: 9904113. DOI: 10.1016/j.lana.2022.100339.

References
1.
Lima S, Queiroz M, Machado L, Vallinoto A, de Oliveira Guimaraes Ishak M, Ishak R . Retrospective epidemiology of the SARS-CoV-2 (and COVID-19) epidemic among 27 Brazilian cities. J Clin Virol Plus. 2022; 1(4):100053. PMC: 8574077. DOI: 10.1016/j.jcvp.2021.100053. View

2.
Malik B, Taylor G . Can we reduce the incidence of adult T-cell leukaemia/lymphoma? Cost-effectiveness of human T-lymphotropic virus type 1 (HTLV-1) antenatal screening in the United Kingdom. Br J Haematol. 2018; 184(6):1040-1043. DOI: 10.1111/bjh.15234. View

3.
Gessain A, Cassar O . Epidemiological Aspects and World Distribution of HTLV-1 Infection. Front Microbiol. 2012; 3:388. PMC: 3498738. DOI: 10.3389/fmicb.2012.00388. View

4.
Laura P, Jose A, Nikki A, Khaled A, Barret J, Jeffery C . Impact of COVID-19 on global burn care. Burns. 2021; 48(6):1301-1310. PMC: 8664090. DOI: 10.1016/j.burns.2021.11.010. View

5.
Nishijima T, Shimada S, Noda H, Miyake K . Towards the elimination of HTLV-1 infection in Japan. Lancet Infect Dis. 2018; 19(1):15-16. DOI: 10.1016/S1473-3099(18)30735-7. View